Cargando…
Panobinostat and Multiple Myeloma in 2018
FDA and EMA approval of panobinostat offers an additional therapeutic option for multiple myeloma; however, adoption of panobinostat has been limited by its adverse event profile. Trials are ongoing to optimize the dosing of panobinostat and to identify its best partners, in order to fully realize t...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AlphaMed Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947458/ https://www.ncbi.nlm.nih.gov/pubmed/29445026 http://dx.doi.org/10.1634/theoncologist.2017-0644 |
| _version_ | 1783322370820276224 |
|---|---|
| author | Yee, Andrew J. Raje, Noopur S. |
| author_facet | Yee, Andrew J. Raje, Noopur S. |
| author_sort | Yee, Andrew J. |
| collection | PubMed |
| description | FDA and EMA approval of panobinostat offers an additional therapeutic option for multiple myeloma; however, adoption of panobinostat has been limited by its adverse event profile. Trials are ongoing to optimize the dosing of panobinostat and to identify its best partners, in order to fully realize the potential of this drug class. |
| format | Online Article Text |
| id | pubmed-5947458 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | AlphaMed Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-59474582018-05-15 Panobinostat and Multiple Myeloma in 2018 Yee, Andrew J. Raje, Noopur S. Oncologist Commentaries FDA and EMA approval of panobinostat offers an additional therapeutic option for multiple myeloma; however, adoption of panobinostat has been limited by its adverse event profile. Trials are ongoing to optimize the dosing of panobinostat and to identify its best partners, in order to fully realize the potential of this drug class. AlphaMed Press 2018-02-14 2018-05 /pmc/articles/PMC5947458/ /pubmed/29445026 http://dx.doi.org/10.1634/theoncologist.2017-0644 Text en © AlphaMed Press 2018 |
| spellingShingle | Commentaries Yee, Andrew J. Raje, Noopur S. Panobinostat and Multiple Myeloma in 2018 |
| title | Panobinostat and Multiple Myeloma in 2018 |
| title_full | Panobinostat and Multiple Myeloma in 2018 |
| title_fullStr | Panobinostat and Multiple Myeloma in 2018 |
| title_full_unstemmed | Panobinostat and Multiple Myeloma in 2018 |
| title_short | Panobinostat and Multiple Myeloma in 2018 |
| title_sort | panobinostat and multiple myeloma in 2018 |
| topic | Commentaries |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947458/ https://www.ncbi.nlm.nih.gov/pubmed/29445026 http://dx.doi.org/10.1634/theoncologist.2017-0644 |
| work_keys_str_mv | AT yeeandrewj panobinostatandmultiplemyelomain2018 AT rajenoopurs panobinostatandmultiplemyelomain2018 |